Suramin suppresses growth, alkaline-phosphatase and telomerase activity of human osteosarcoma cells in vitro.
Neoadjuvant chemotherapy in osteosarcoma improves the survival dramatically, but there is currents drug resistance in about 25% of patients, leading researchers to investigate alternative therapy forms. Suramin has in the last two decades been used as salvage therapy in some cancers. This study was undertaken to investigate suramin as a possible salvage therapy in osteosarcoma. The effect of suramin on three human osteosarcoma cell lines (MG-63, HOS and SaOS-2) and three primary osteosarcoma cell lines isolated from biopsies was investigated. Suramin significantly inhibited cell proliferation, determined by 3H-thymidine incorporation, of osteosarcoma cells at a dose ranging from 250 to 500 microg/ml. Suramin decreased the secretion of alkaline-phosphatase after stimulation by 1,25-dihydroxy-Vitamin D(3) up to 50% and decreased telomerase activity by up to 40%. The data demonstrate that suramin has marked in vitro effects on human osteosarcoma cells supporting further clinical investigation.
Trieb
K
K
Department of Orthopedics, University of Vienna, Währingergürtel 18-20, Vienna 1090, Austria. klemens.trieb@akh-wien.ac.at
Blahovec
H
H
D000469:Alkaline Phosphatase / Q000037:antagonists & inhibitors*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000201:enzymology* / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D012516:Osteosarcoma / Q000201:enzymology* / Q000473:pathology; D013498:Suramin / Q000494:pharmacology*; D019098:Telomerase / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D013498:Suramin; D019098:Telomerase; D000469:Alkaline Phosphatase